SEC Company Response from Zomedica Corp. (ZOM) (CIK 0001684144) (ZOMDF) — May 20, 2020
Zomedica Corp. (ZOM) (CIK 0001684144)
Date: May 20, 2020 · CIK: 0001684144 · Accession: 0001171843-20-003904
AI Filing Summary & Sentiment
File numbers found in text: 333-238322
Letter
Zomedica Pharmaceuticals Corp.
100 Phoenix Drive, Suite 180
Ann Arbor, Michigan 48108
May 20, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Zomedica Pharmaceuticals Corp. (the “Company”)
Registration Statement on Form S-1, as amended (File No. 333-238322)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 9:00 a.m., Eastern Time, on May 26, 2020, or as soon as practicable thereafter.
Please call John D. Hogoboom of Lowenstein Sandler LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
May 20, 2020
Page 2
Very truly yours,
ZOMEDICA PHARMACEUTICALS CORP.
Show Raw Text
CORRESP
1
filename1.htm
Zomedica Pharmaceuticals Corp.
100 Phoenix Drive, Suite 180
Ann Arbor, Michigan 48108
May 20, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Zomedica Pharmaceuticals Corp. (the “Company”)
Registration Statement on Form S-1, as amended (File No. 333-238322)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 9:00 a.m., Eastern Time, on May 26, 2020,
or as soon as practicable thereafter.
Please call John D. Hogoboom of Lowenstein Sandler
LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
May 20, 2020
Page 2
Very truly yours,
ZOMEDICA PHARMACEUTICALS CORP.
By: /s/ Shameze Rampertab
Name: Shameze Rampertab
Title: Interim Executive Officer and Chief Financial Officer
- 2 -